Cargando…

Pirfenidone Sensitizes NCI-H460 Non-Small Cell Lung Cancer Cells to Paclitaxel and to a Combination of Paclitaxel with Carboplatin

Pirfenidone, an antifibrotic drug, has antitumor potential against different types of cancers. Our work explored whether pirfenidone sensitizes non-small cell lung cancer (NSCLC) cell lines to chemotherapeutic treatments. The cytotoxic effect of paclitaxel in combination with pirfenidone against thr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Branco, Helena, Oliveira, Júlio, Antunes, Catarina, Santos, Lúcio L., Vasconcelos, Maria Helena, Xavier, Cristina P. R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998757/ https://www.ncbi.nlm.nih.gov/pubmed/35408988 http://dx.doi.org/10.3390/ijms23073631

Ejemplares similares

Pharmacokinetics and tissue distribution of PGG–paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts
por: Wang, Xinghe, et al.
Publicado: (2009)

Radiosensitizing effect of carboplatin and paclitaxel to carbon-ion beam irradiation in the non-small-cell lung cancer cell line H460
por: Kubo, Nobuteru, et al.
Publicado: (2015)

An Aqueous Extract of Tuberaria lignosa Inhibits Cell Growth, Alters the Cell Cycle Profile, and Induces Apoptosis of NCI-H460 Tumor Cells
por: Pereira, Joana M., et al.
Publicado: (2016)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
por: Tan, Xiangbin, et al.
Publicado: (2023)

A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782)
por: Leal, Ticiana A., et al.
Publicado: (2022)

Schedule-Dependent Effect of Epigallocatechin-3-Gallate (EGCG) with Paclitaxel on H460 Cells
por: Park, Sunghoon, et al.
Publicado: (2014)

A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013
por: Ademuyiwa, Foluso O., et al.
Publicado: (2022)

Ischemic Colitis Associated with Paclitaxel and Carboplatin Combination
por: Elsayed, Ahmed Gamal, et al.
Publicado: (2017)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
por: Tao, Yin, et al.
Publicado: (2022)

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
por: Dessai, S. B., et al.
Publicado: (2016)

Primary high-grade serous ovarian cancer cells are sensitive to senescence induced by carboplatin and paclitaxel in vitro
por: Uruski, Paweł, et al.
Publicado: (2021)

Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non‐Small Cell Lung Cancer
por: Takayama, Koichi, et al.
Publicado: (2019)

A Case of Metastatic Basosquamous Basal Cell Carcinoma Treated With Carboplatin and Paclitaxel
por: Papageorgiou, Chryssoula, et al.
Publicado: (2023)

Sufentanil impairs autophagic degradation and inhibits cell migration in NCI-H460 in vitro
por: Jiang, Hui, et al.
Publicado: (2019)

Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines
por: Eng, Lawson, et al.
Publicado: (2011)

Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel
por: Jilaveanu, Lucia B., et al.
Publicado: (2013)

CARBOPLATIN-PACLITAXEL INDUCED ACUTE MULTI-VESSEL CORONARY THROMBOSIS
por: Fanous, Hanna, et al.
Publicado: (2022)

PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials
por: de Moraes, Francisco Cezar Aquino, et al.
Publicado: (2023)

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale
por: Isakoff, Steven J, et al.
Publicado: (2017)

Chemoradiation with Weekly Paclitaxel and Carboplatin in Esophageal Squamous Cell Carcinoma: A Prospective Study
por: Joseph, Deepa M., et al.
Publicado: (2021)

Combined anticancer activity of osthole and cisplatin in NCI-H460 lung cancer cells in vitro
por: XU, XIAO-MAN, et al.
Publicado: (2013)

nab-Paclitaxel in Combination with Carboplatin for a Previously Treated Thymic Carcinoma
por: Makimoto, Go, et al.
Publicado: (2014)

Carboplatin/paclitaxel: COVID-19 induced neutropenic enterocolitis : case report
Publicado: (2021)

Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma
por: Takahashi, Akiko, et al.
Publicado: (2022)

Metformin synergistically enhances antiproliferative effects of cisplatin and etoposide in NCI-H460 human lung cancer cells
por: Teixeira, Sarah Fernandes, et al.
Publicado: (2013)

Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery
por: Mullany, Sally, et al.
Publicado: (2020)

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer
por: Huang, Chen-Yu, et al.
Publicado: (2020)

Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab−Paclitaxel and Maintenance Monotherapy with nab−Paclitaxel: Two Case Reports
por: Araya, Tomoyuki, et al.
Publicado: (2020)

Ginsenoside Rg5 Sensitizes Paclitaxel—Resistant Human Cervical-Adeno-Carcinoma Cells to Paclitaxel—And Enhances the Anticancer Effect of Paclitaxel
por: Ramesh, Janani, et al.
Publicado: (2022)

Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis
por: Chen, Yingkai, et al.
Publicado: (2022)

Molecular alterations in apoptotic pathways after PKB/Akt-mediated chemoresistance in NCI H460 cells
por: Hövelmann, S, et al.
Publicado: (2004)

Effects of sequential paclitaxel–carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study
por: Wang, Fei, et al.
Publicado: (2016)

First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report
por: Funaishi, Kunihiko, et al.
Publicado: (2017)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

PBK attenuates paclitaxel‐induced autophagic cell death by suppressing p53 in H460 non‐small‐cell lung cancer cells
por: Park, Jung‐Hwan, et al.
Publicado: (2020)

Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment
por: Heijns, Joan B., et al.
Publicado: (2008)

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.
por: Siddiqui, N., et al.
Publicado: (1997)

A Case of Biphasic Pulmonary Blastoma Treated with Carboplatin and Paclitaxel plus Bevacizumab
por: Sakata, Shinya, et al.
Publicado: (2015)

Repetitive responses to nanoparticle albumin‐bound paclitaxel and carboplatin in malignant pleural mesothelioma
por: Kanai, Osamu, et al.
Publicado: (2016)

Survival outcomes in patients with oropharyngeal cancer treated with carboplatin/paclitaxel and concurrent radiotherapy
por: Roskies, M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vm5tked41sgqsp4689r4qlipp5